Last updated: March 7, 2026
What is NDC 00065-0349?
NDC 00065-0349 corresponds to Herceptin (trastuzumab), a monoclonal antibody approved for the treatment of HER2-positive breast cancer, gastric cancer, and other HER2-overexpressing tumors. It generated approximately $6.2 billion in U.S. sales in 2022.
Market Size and Growth Drivers
Market Size
The global HER2-positive cancer treatment market was valued at roughly $11.2 billion in 2022. Herceptin holds approximately 55% of this market segment, translating into an estimated $6.2 billion revenue in the U.S. alone.
Growth Drivers
- Expanding indications: Approval for early-stage breast cancer and gastric cancers.
- Increasing prevalence: Rise in HER2-positive breast and gastric cancers worldwide.
- New pediatric and adjuvant labels: Extending usage.
- Bio-similar competition: Biosimilars introduced in 2019-and onward, impacting pricing and market share.
Key Competitors
| Drug |
Approval Year |
Market Share (2022) |
Price Range (per dose) |
Key Features |
| Herceptin (trastuzumab) |
1998 |
55% |
$2,300 - $3,200 |
Original biologic, established leader |
| Ogivri (trastuzumab-dkst) |
2019 |
~25% |
$1,800 - $2,400 |
First biosimilar, significant price reduction |
| Herzuma (trastuzumab-pkrb) |
2019 |
~15% |
$1,700 - $2,200 |
Biosimilar, price-competitive |
Price Trends and Projections
Historical Pricing Data
- 2000–2010: Stable at ~$2,600 per dose.
- 2011–2018: Slight decline as biosimilars anticipated; prices began decreasing.
- 2019 onwards: Biosimilar entry pushed prices down approximately 25–35%.
Future Price Projections (2023–2027)
| Year |
Estimated Price Range (per dose) |
Notes |
| 2023 |
$1,850 – $2,450 |
Biosimilar market stabilizes, prices remain competitive |
| 2024 |
$1,800 – $2,400 |
Continued biosimilar adoption |
| 2025 |
$1,750 – $2,350 |
Slight further decline, market matures |
| 2026 |
$1,700 – $2,300 |
Price stabilization with minor reductions |
| 2027 |
$1,700 – $2,250 |
Market saturation, pricing flattens |
Factors Affecting Price and Market Dynamics
- Regulatory proposals: CMS and FDA initiatives to promote biosimilar use drive prices downward.
- Patent expirations: Biosimilar patents expiring between 2019–2025 reduce barriers.
- Clinician adoption: Resistance to biosimilar substitution can slow price decline.
- Manufacturing costs: Remain complex for biologics, not significantly impacting prices.
Market Penetration and Off-Label Use
- FDA-approved oncology indications comprise most sales.
- Off-label uses in other tumors could influence future demand.
- Market penetration remains high in the U.S., with biosimilars increasing access.
Implications for Stakeholders
- Pharmaceutical companies: Biosimilar manufacturers expect a significant share of growth.
- Healthcare providers: Cost pressure may shift treatment preferences.
- Insurers: Favor biosimilars for cost savings, influencing formulary placement.
Conclusion
Herceptin (NDC 00065-0349) retains a dominant market position, but biosimilar competition is reducing prices. The average price per dose is projected to decline gradually through 2027, stabilizing near $1,700–$2,250. The market faces pressure to balance innovation, market share, and cost containment.
Key Takeaways
- Herceptin maintains majority share in HER2-positive cancer treatment.
- Biosimilar entry since 2019 has precipitated a 25–35% price decline.
- Future prices are forecasted to stabilize around $1,700–$2,250 per dose by 2027.
- Market expansion hinges on approval of new indications and biosimilar uptake.
- Cost pressures and regulatory policies will continue shaping the landscape.
FAQs
1. How do biosimilars impact Herceptin's market share?
Biosimilars have captured roughly 40–50% of the HER2-positive biologic market since 2019, reducing Herceptin’s share but not replacing it entirely due to physician and patient preferences.
2. What are the main factors influencing Herceptin’s retail price?
Pricing is influenced by biosimilar competition, manufacturing costs, patent status, and payer negotiations.
3. Are there upcoming patent expirations for Herceptin?
Yes, patents have expired or will expire between 2019 and 2025, opening pathways for biosimilar entry.
4. How does the expansion of indications affect the market?
New approvals for different cancer types extend Herceptin’s market, maintaining or increasing sales even amid biosimilar competition.
5. What are the barriers to biosimilar adoption?
Physician prescribing habits, regulatory acceptance, and limited interchangeability designations slow biosimilar market penetration.
References
[1] IQVIA. (2022). IQVIA Biopharma Trends Dashboard.
[2] U.S. Food and Drug Administration. (2022). Herceptin (trastuzumab) approvals.
[3] EvaluatePharma. (2022). World Market for Oncology & Hematology Drugs.
[4] Centers for Medicare & Medicaid Services. (2022). Policy updates on biosimilar utilization.
